Summary
Zopiclone is a cyclopyrrolone hypnotic agent. It possesses a chiral centre and is commercially available as a racemic mixture. Methods involving high performance liquid chromatography (HPLC), gas chromatography, capillary electrophoresis (CE) and high performance thin layer chromatography have been developed for the quantitation of zopiclone and its 2 main metabolites in biological samples. For the chiral determination of the enantiomers of zopiclone and its metabolites, HPLC and CE methods are available.
After oral administration, zopiclone is rapidly absorbed, with a bioavailability of approximately 80%. The plasma protein binding of zopiclone has been reported to be between 45 and 80%. Zopiclone is rapidly and widely distributed to body tissues including the brain, and is excreted in urine, saliva and breast milk.
Zopiclone is partly metabolised in the liver to form an inactive N-demethylated derivative and an active N-oxide metabolite. In addition, approximately 50% of the administered dose is decarboxylated and excreted via the lungs. Less than 7% of the administered dose is renally excreted as unchanged zopiclone. In urine, the N-demethyl and N-oxide metabolites account for 30% of the initial dose. The terminal elimination half-life (t1/2z) of zopiclone ranges from 3.5 to 6.5 hours.
The pharmacokinetics of zopiclone in humans are stereoselective. After oral administration of the racemic mixture, Cmax (time to maximum plasma concentration), AUG (area under the plasma time-concentration curve) and t1/2z values are higher for the dextrorotatory enantiomer owing to the slower total clearance and smaller volume of distribution (corrected by the bioavailability), compared with the levorotatory enantiomer. In urine, the concentrations of the dextrorotatory enantiomers of the N-demethyl and N-oxide metabolites are higher than those of the respective antipodes.
The pharmacokinetics of zopiclone are altered by aging and are influenced by renal and hepatic functions. Drug interactions have been observed with erythromycin, trimipramine and carbamazepine.
Similar content being viewed by others
References
Hempel G, Blaschke G. Enantioselective determination of zopiclone and its metabolites by capillary electrophoresis. J Chromatogr. In press
Fernandez C, Gimenez F, Mayrargue J, et al. Degradation and racemization of zopiclone enantiomers in plasma and partially aqueous solutions. Chirality 1995; 7: 267–71
Gaillot J, Heusse D, Houghton GW, et al. Pharmacokinetics and metabolism of zopiclone. Pharmacology 1983; 27Suppl. 2: 76–91
Stanley C, Mitchell P, Kaye CM. Simple and sensitive method for monitoring zopiclone in plasma by high-performance liquid chromatography with fluorescence detection. Analyst 1985; 110: 83–4
Le Liboux A, Frydman A, Gaillot J. Simultaneous determination of zopiclone and its two major metabolites (N-oxide and N-desmethyl) in human biological fluids by reversed-phase high-performance liquid chromatography. J Chromatogr 1987; 417: 151–8
Tracqui A, Kintz P, Mangin P. High-performance liquid chromatography assay with diode-array detection for toxicological screening of zopiclone, Zolpidem, suriclone and alpidem in human plasma. J Chromatogr 1993; 616: 95–103
Royer-Morrot MJ, Rambourg M, Jacob I, et al. Determination of zopiclone in plasma using column liquid chromatography with ultraviolet detection. J Chromatogr 1992; 581: 297–9
Fernandez C, Gimenez F, Baune B, et al. Determination of the enantiomers of zopiclone and its two chiral metabolites in urine using an automated coupled achiral-chiral chromatographic system. J Chromatogr 1993; 617: 271–8
Miller LG, Leduc BW, Greenblatt DJ. Determination of zopiclone in plasma by liquid chromatography with application to steady-state monitoring. J Chromatogr 1986; 380: 211–5
Foster RT, Caille G, Anh Ho Ngoc, et al. Stereospecific high-performance liquid chromatographic assay of zopiclone in human plasma. J Chromatogr 1994; 658: 161–6
Blaschke G, Hempel G, Muller WE. Preparative and analytical separation of the zopiclone enantiomers and determination of their affinity to the benzodiazepine receptor binding site. Chirality 1993; 5: 419–21
Fernandez C, Baune B, Gimenez F, et al. Determination of zopiclone enantiomers in plasma using a chiral cellulose carbamate column. J Chromatogr 1991; 572: 195–202
Ahrens B, Schutz H, Seno H, et al. Screening, identification and determination of the two new hypnotics Zolpidem and zopiclone. Arzneim Forsch 1994; 44: 799–802
Debruyne D, Lacotte J, Hurault de Ligny B, et al. Determination of Zolpidem and zopiclone in serum by capillary column gas chromatography. J Pharm Sci 1991; 80: 71–4
Gaillard Y, Gay-Montchamp JP, Ollagnier M. Gas chromatographic determination of zopiclone in plasma after solid-phase extraction. J Chromatogr 1993; 619: 310–4
Kennel S, Kintz P, Tracqui A, et al. Identification and quantitation in plasma of zopiclone by gas chromatography with nitrogen-phosphorus detection. J Chromatogr 1990; 527: 169–73
Boniface PJ, Martin IC, Nolan SL, et al. Development of a method for the determination of zopiclone in whole blood. J Chromatogr 1992; 584: 199–206
Howard PJ, McLean E, Dundee JW. High performance liquid chromatography and fluorescence detection in the estimation of zopiclone in plasma samples. Proceedings of the British Pharmacology Society; 1985 Dec 18–20. Br J Clin Pharmacol 1986; 21(5): 614
Caille G, Dufouich P, Spenard J, et al. Pharmacokinetic and clinical parameters of zopiclone and trimipramine when administered simultaneously to volunteers. Biopharm Drug Dispos 1984; 5: 117–25
Channer KS, Dent M, Roberts CJC. The effect of posture at the time of administration on the central depressant effects of the new hypnotic zopiclone. Br J Clin Pharmacol 1984; 18: 879–86
Fernandez C, Maradeix V, Gimenez F, et al. Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. Drug Metab Dispos 1993; 21: 1125–8
Houghton GW, Dennis MJ, Trempleton R, et al. A repeated dose pharmacokinetic study of a new hypnotic agent, zopiclone. Int J Clin Pharmacol Ther Toxicol 1985; 23: 97–100
Matheson I, Sande HA, Gaillot J. The excretion of zopiclone into breast milk. Br J Clin Pharmacol 1990; 30: 267–71
Parker G, Roberts CJC. Plasma concentrations and central nervous system effects of the new hypnotic agent zopiclone in patients with chronic liver disease. Br J Clin Pharmacol 1983; 16: 259–65
Goa KL, Heel RC. Zopiclone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. Drugs 1986; 32: 48–65
Blanchard JC, Boireau A, Julou L. Brain receptors and zopiclone. Pharmacology 1983; 17Suppl. 2: 59–63
Byrnes JJ, Greenblatt DJ. Benzodiazepine receptor binding of non-benzodiazepines in vivo: alpidem, Zolpidem and zopiclone. Brain Res Bull 1992; 29: 905–8
Trifiletti RR, Snyder SH. Anxiolytic cyclopyrrolones zopiclone and suriclone bind to a novel site linked allosterically to benzodiazepine receptors. Mol Pharmacol 1984; 26: 458–69
Pounder DJ, Davies JI. Zopiclone poisoning: tissue distribution and potential for postmortem diffusion. Forensic Sci Int 1993; 65: 177–83
Hempel G, Blaschke G. Enantioselective metabolism of zopiclone in vitro and in vivo. Presented at 5th International Symposium on Chiral Discrimination; Stockholm, 1994
Gaillot J, Le Roux Y, Houghton GW, et al. Clinical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. Sleep 1987; 10Suppl. 1: 7–21
Viron B, De Meyer M, Le Riboux A, et al. Steady state pharmacokinetics of zopiclone during multiple oral dosing (7.5 mg) in patients with severe chronic renal failure. Int Clin Psychopharmacol 1990; 5Suppl. 2: 95–104
Marc Aurélé J, Caille J, Bourgoin J. Comparison of zopiclone pharmacokinetics in patients with impaired renal fonction and nomal subjects. Effect of hemodialysis. Sleep 1987; 10Suppl. 1: 22–6
Aranko K, Luurila H, Backman JT, et al. The effect of erythromycine on the pharmacokinetics and pharmacodynamics of zopiclone. Br J Clin Pharmacol 1994; 38: 363–7
Larivière L, Caille G, Elie R. The effects of low and moderate doses of alcohol on the pharmacokinetics parameters of zopiclone. Biopharm Drug Dispos 1986; 7: 207–10
Saano V, Hansen PP, Paronen P. Interactions and comparative effects of zopiclone, diazepam and lorazepam on psychomotor performance and elimination pharmacokinetics in healthy volunteers. Pharmacol Toxicol 1992; 70: 135–9
Seppälä T, Nuotto E, Dreyfus JF. Drug alcohol interactions on psychomotor skills: zopiclone and flunitrazepam. Pharmacology 1983; 27Suppl. 2: 127–35
Kuitunen T, Mattila MJ, Seppälä T, et al. Actions of zopiclone and carbamazepine, alone and in combination on human skilled performance in laboratory and clinical tests. Br J Clin Pharmacol 1990; 30: 453–61
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fernandez, C., Martin, C., Gimenez, F. et al. Clinical Pharmacokinetics of Zopiclone. Clin. Pharmacokinet. 29, 431–441 (1995). https://doi.org/10.2165/00003088-199529060-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199529060-00004